Advertisement

Immunologic Research

, Volume 66, Issue 5, pp 605–610 | Cite as

Long-term persistence of anti-rods and rings antibodies in patients with chronic hepatitis C after antiviral treatment

  • Ana Beatriz da Silva Sacerdote
  • Norma Arteiro Filgueira
  • Silvana de Barros Barreto
  • Andréa Dória Batista
  • Edmundo Pessoa Lopes
Original Article

Abstract

Anti-rods and rings (anti-RR) antibodies are related to hepatitis C virus (HCV) in patients treated with pegylated interferon (PEG-IFN) and ribavirin (RBV). Only RBV induces rods/rings structures in vitro; but in vivo, the antibody appearance is related to the combination of these drugs, because data about patients using just one of these drugs alone is missing. Some studies suggest disappearance of these antibodies over time. The aim of this study was to describe the occurrence of anti-RR in patients with chronic hepatitis C treatment-naïve or previously PEG-IFN/RBV-experienced, evaluating the persistence of anti-RR antibodies long after PEG-IFN/RBV treatment. From 2016 to 2017, 70 HCV-infected patients were screened for anti-RR using indirect immunofluorescence. Demographic and clinical data about previous treatments against HCV were assessed. Thirty-four patients (49%) had been previously treated with PEG-IFN/RBV and the average time since they had received the last antiviral treatment was 85.4 months. Anti-RR seropositivity was detected in 16 patients (23%), and all of these had used PEG-IFN/RBV (corresponding to 47% of experienced patients). Previous antiviral treatment and previous exposure time to RBV were associated with anti-RR positivity. Median time elapsed since last treatment was similar between anti-RR-positive and anti-RR-negative patients. Anti-RR seropositivity was not observed in treatment-naïve patients, but was detected in almost half of patients previously treated with PEG-IFN and RBV, even after a long period without exposure to these drugs. This antibody was related to extended prior exposure to ribavirin.

Keywords

Chronic hepatitis C Autoantibodies IMPDH enzyme Ribavirin Antiviral therapy 

Notes

Acknowledgments

We thank the patients who participate in this study. We also appreciate the help of Caroline Louise Diniz Pereira with the collection of samples and Emídio Cavalcanti de Albuquerque with the statistical analysis. The English text of this paper has been revised by Sidney Pratt, Canadian, MAT (The Johns Hopkins University), RSAdip - TESL (Cambridge University).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1):S58–68.CrossRefGoogle Scholar
  2. 2.
    Stroffolini T, Colloredo G, Gaeta GB. Does an “autoimmune”profile affect the clinical profile of chronic hepatitis C? An Italian multicentre survey. J Viral Hepat. 2004;11(3):257–62.CrossRefGoogle Scholar
  3. 3.
    Yee LJ, Kelleher P, Goldin RD, Marshall S, Thomas HC, Alberti A, et al. Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. J Viral Hepat. 2004;11(5):459–64.CrossRefGoogle Scholar
  4. 4.
    Peng Y, Hsieh S, Yang D, Tung C, Hu W, Huang W. Expression and clinical significance of antinuclear antibody in hepatitis C virus infection. J Clin Gastroenterol. 2001;33(5):402–6.CrossRefGoogle Scholar
  5. 5.
    Williams MJ, Lawson A, Neal KR, Ryder SD, Irving WL. Autoantibodies in chronic hepatitis C virus infection and their association with disease profile. J Viral Hepat. 2009;16(5):325–31.CrossRefGoogle Scholar
  6. 6.
    Cocquerel L, Kuo C-C, Dubuisson J, Levy S. CD81-dependent binding of hepatitis C virus E1E2 heterodimers. J Virol. 2003;77(19):10677–83.CrossRefGoogle Scholar
  7. 7.
    Covini G, Carcamo WC, Bredi E, Von Mühlen CA, Colombo M, Chan EKL. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Antivir Ther. 2012;17(5):805–11.CrossRefGoogle Scholar
  8. 8.
    Lopes EP, Silva AE, Sette Júnior H, Guimarães RX, Ferraz ML. Autoantibodies before, during and after administration of recombinant interferon-a for chronic viral hepatitis. Rev Inst Med trop S Paulo. 1995;37(5):455–60.CrossRefGoogle Scholar
  9. 9.
    Novembrino C, Aghemo A, Ferraris Fusarini C, Maiavacca R, Matinato C, Lunghi G, et al. Interferon-ribavirin therapy induces serum antibodies determining “rods and rings” pattern in hepatitis C patients. J Viral Hepat. 2014;21(12):944–9.CrossRefGoogle Scholar
  10. 10.
    Keppeke GD, Nunes E, Ferraz MLG, Silva EAB, Granato C, Chan EKL, et al. Longitudinal study of a human drug-induced model of autoantibody to cytoplasmic rods/rings following HCV therapy with ribavirin and interferon-α. PLoS One. 2012;7(9).CrossRefGoogle Scholar
  11. 11.
    Carcamo WC, Ceribelli A, Calise SJ, Krueger C, Liu C, Daves M, et al. Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients. J Clin Immunol. 2013;33(2):420–6.CrossRefGoogle Scholar
  12. 12.
    Calise SJ, Bizzaro N, Nguyen T, Bassetti D, Porcelli B, Almi P, et al. Anti-rods/rings autoantibody seropositivity does not affect response to telaprevir treatment for chronic hepatitis C infection. Autoimmun Highlights. 2016;7(1):1–6.CrossRefGoogle Scholar
  13. 13.
    Chan EKL, Damoiseaux J, Carballo OG, Conrad K, de Melo CW, Francescantonio PLC, et al. Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns (ICAP) 2014-2015. Front Immunol. 2015;6.Google Scholar
  14. 14.
    Dammermann W, Polywka S, Dettmann I, Mindorf S, Komorowski L, Wehmeyer M, et al. Autoantibodies against “rods and rings”-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a “real life” cohort. Med Microbiol Immunol. 2017;206(5):379–82.CrossRefGoogle Scholar
  15. 15.
    Keppeke GD, John Calise S, Chan EK, Andrade LEC. Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy. World J Gastroenterol. 2016;22(6):1966–74.CrossRefGoogle Scholar
  16. 16.
    Shaikh Y, Krantz A, El-Farra Y. Anti-rods and rings autoantibodies can occur in the hepatitis C-naïve population. J Prev Med Hyg. 2013;54(3):175–80.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Keppeke GD, Satoh M, Ferraz MLG, Chan EKL, Andrade LEC. Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α. Immunol Res. 2014;60(1):38–49.CrossRefGoogle Scholar
  18. 18.
    Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol. 1999;30(3):394–401.CrossRefGoogle Scholar
  19. 19.
    Faria AC, Barcellos KSA, Andrade LEC. Longitudinal fluctuation of antibodies to extractable nuclear antigens in systemic lupus erythematosus. J Rheumatol. 2005;32(7):1267–72.PubMedGoogle Scholar
  20. 20.
    Vadasz Z, Haj T, Kessel A, Toubi E. Age-related autoimmunity. BMC Med 2013;11(1):1.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Ana Beatriz da Silva Sacerdote
    • 1
  • Norma Arteiro Filgueira
    • 2
  • Silvana de Barros Barreto
    • 3
  • Andréa Dória Batista
    • 2
  • Edmundo Pessoa Lopes
    • 2
  1. 1.Postgraduate Program in Health Sciences CenterUniversidade Federal de PernambucoRecifeBrazil
  2. 2.Department of Gastroenterology and Hepatology, Hospital das ClínicasUniversidade Federal de PernambucoRecifeBrazil
  3. 3.Clinical Laboratory, Hospital das ClínicasUniversidade Federal de PernambucoRecifeBrazil

Personalised recommendations